Compare IOP Reduction

15 products »

close Created with Sketch.

Rhopressa

Aerie Pharmaceuticals, Inc

Rhopressa (netarsudil ophthalmic solution) 0.02% is a rho kinase inhibitor indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Rhopressa only requires one drop of medication per day, taken in the evening.

At-a-Glance
  • Mechanism of Action: Netarsudil is a rho kinase inhibitor, which is believed to reduce IOP by increasing the outflow of aqueous humor through the trabecular meshwork route. The exact mechanism is unknown.
  • Dosage: The recommended dosage is one drop once daily in the evening.

Details

FDA

Yes

CE Mark

Not specified

Active Ingredients

Netarsudil

Application

Topical

Status

Prescription

Strength

0.02%

From Your Peers

Newly Approved Glaucoma Therapy Increases Options for Patients and Providers

READ ARTICLE »

Show More

Company Information

Contact the company for additional information, availability, or pricing:

Aerie Pharmaceuticals, Inc

aeriepharma.com

4301 Emperor Blvd

Durham, NC 27703